Multidisciplinary Approaches to Tumor Immunology

肿瘤免疫学的多学科方法

基本信息

  • 批准号:
    10472619
  • 负责人:
  • 金额:
    $ 15.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-09-01 至 2023-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT The overarching goals of the Tumor Immunology Training Program (TITP) at the Roswell Park Cancer Institute (RPCI) Graduate Division are to educate, train and prepare talented pre-doctoral students for a profession in cancer immunology research. Driven by significant advances in understanding how the immune system can be weaponized against cancer, future leaders in tumor immunology will not only be well-trained in the discipline, but also will have a strong appreciation of the potential translational impact to human cancer biology and therapy. The unique, cancer-focus within the TITP introduces trainees to an advanced didactic and conceptual cancer immunology educational paradigm that encapsulates knowledge spanning the continuum of basic science to clinical application. The uniqueness of this TITP is further enhanced by the integration of an academic environment comprised of diverse faculty concentrated within a prestigious NCI-designated Comprehensive Cancer Center. Trainees are exposed to a comprehensive portfolio of cancer-related topics that will be enhanced through a new “umbrella” academic curriculum starting in the fall of 2018. It is during the first year of study when trainees will select the tumor immunology-specific “track” and then conduct their doctoral research with TITP faculty with expertise in basic, translational, or clinical sciences. The primary mission of the training grant renewal is to support competitively selected students during their third and fourth years of study. The funds requested cover stipends and tuition for 4 pre-doctoral students per year. This funding is crucial to continue the upward trajectory experienced for nearly 15 years of NRSA support in the quality and diversity of pre-doctoral trainees focused on complex and challenging immunologic questions in cancer. NRSA-supported trainees are prepared for a competitive biomedical career through didactic lectures and concept-driven learning in tumor immunology and biology, grant writing and ethical conduct of research. After completing all formal course work, degree conferral is dependent upon passing the preliminary exam, fulfilling a first-authored publication requirement, and passing the dissertation defense reflecting the novel and original findings of the student's body-of-work. Trainees who complete this TITP will be well-versed in all major facets of tumor immunology and will have the solid foundation upon which to build cancer-focused careers, guided by a clear vision of its impact on human cancer biology and treatment.
项目总结/摘要 罗斯威尔公园癌症研究所肿瘤免疫学培训计划(TITP)的总体目标 (RPCI)研究生部是教育,培训和准备有才华的博士前学生的职业, 癌症免疫学研究。在理解免疫系统如何 作为对抗癌症的武器,肿瘤免疫学的未来领导者不仅要在 学科,但也将有潜在的翻译对人类癌症生物学的影响强烈赞赏 和心理治疗TITP内独特的癌症焦点向学员介绍了先进的教学和 概念性癌症免疫学教育范式,涵盖了跨越以下连续体的知识 从基础科学到临床应用。该TITP的独特性通过集成 学术环境由不同的教师集中在一个著名的NCI指定 综合癌症中心。学员接触到一个全面的组合与癌症有关的主题 这将通过2018年秋季开始的新的“总括”学术课程得到加强。正是在 第一年的学习时,学员将选择肿瘤免疫学特异性的“轨道”,然后进行他们的 博士研究与TITP教师在基础,转化或临床科学的专业知识。主 培训补助金更新的使命是支持竞争性选择的学生在他们的第三和第四 多年的研究。申请的资金包括每年4名博士预科生的津贴和学费。这 资金是至关重要的继续上升轨迹经历了近15年的NRSA的支持, 博士前学员的素质和多样性专注于复杂且具有挑战性的免疫学问题, 癌NRSA支持的学员通过教学讲座为竞争性的生物医学职业做好准备 以及肿瘤免疫学和生物学的概念驱动学习,资助写作和研究的道德行为。 完成所有正式课程后,学位授予取决于通过初步考试, 满足第一作者的出版要求,并通过论文答辩反映小说和 学生的工作的原始发现。完成本TITP的学员将精通所有专业 肿瘤免疫学的各个方面,并将有坚实的基础上建立癌症为重点的职业生涯, 它对人类癌症生物学和治疗的影响有着清晰的愿景。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Scott I. Abrams其他文献

Differences in Immune Cell Populations between Individuals with or without MGUS
  • DOI:
    10.1182/blood-2024-206171
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Sawyer Bawek;Janine M. Joseph;Alan Hutson;Sarah Parker;Joseph D. Tario Jr;Hamza Hassan;Scott I. Abrams;Jens Hillengass
  • 通讯作者:
    Jens Hillengass
Influence of interferon γ on modulation of Fas expression by human colon carcinoma cells and their subsequent sensitivity to antigen-specific CD8+ cytotoxic T lymphocyte attack
  • DOI:
    10.1007/s002620000105
  • 发表时间:
    2000-06-01
  • 期刊:
  • 影响因子:
    5.100
  • 作者:
    Elke S. Bergmann-Leitner;Scott I. Abrams
  • 通讯作者:
    Scott I. Abrams
Immune response to a carcinoembryonic antigen polynucleotide vaccine.
对癌胚抗原多核苷酸疫苗的免疫反应。
  • DOI:
  • 发表时间:
    1994
  • 期刊:
  • 影响因子:
    11.2
  • 作者:
    R. Conry;A. Lobuglio;Judy Kantor;Jeffrey Schlom;F. Loechel;S. Moore;L. Sumerel;D. L. Barlow;Scott I. Abrams;David T. Curici
  • 通讯作者:
    David T. Curici
Immune Markers of Multiple Myeloma Patients Demonstrate Significant Change after Participation in Six-Month Physical Activity Intervention
  • DOI:
    10.1182/blood-2022-167655
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Janine M. Joseph;Michaela Hillengass;Hillary Jacobson;Joseph D. Tario;Kristopher Attwood;Adrienne Groman;Rikki Cannioto;Bryan Wittmeyer;Kirsten Moysich;Scott I. Abrams;Jens Hillengass
  • 通讯作者:
    Jens Hillengass
Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules.
通过表达 B7-1 或 B7-2 共刺激分子的重组痘苗病毒诱导抗肿瘤免疫。
  • DOI:
  • 发表时间:
    1994
  • 期刊:
  • 影响因子:
    11.2
  • 作者:
    J. Hodge;Scott I. Abrams;J. Schlom;Judy Kantor
  • 通讯作者:
    Judy Kantor

Scott I. Abrams的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Scott I. Abrams', 18)}}的其他基金

Impact of Circulating Myeloid Cell Clusters on Anti-Tumor Immunity
循环骨髓细胞簇对抗肿瘤免疫的影响
  • 批准号:
    10322156
  • 财政年份:
    2021
  • 资助金额:
    $ 15.13万
  • 项目类别:
Development of a Novel Immunotherapy Platform for Triple-Negative Breast Cancer
开发针对三阴性乳腺癌的新型免疫治疗平台
  • 批准号:
    10463811
  • 财政年份:
    2021
  • 资助金额:
    $ 15.13万
  • 项目类别:
Development of a Novel Immunotherapy Platform for Triple-Negative Breast Cancer
开发针对三阴性乳腺癌的新型免疫治疗平台
  • 批准号:
    10287834
  • 财政年份:
    2021
  • 资助金额:
    $ 15.13万
  • 项目类别:
Impact of Circulating Myeloid Cell Clusters on Anti-Tumor Immunity
循环骨髓细胞簇对抗肿瘤免疫的影响
  • 批准号:
    10543820
  • 财政年份:
    2021
  • 资助金额:
    $ 15.13万
  • 项目类别:
Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry
肿瘤免疫环境和乳腺癌差异:针对非洲和欧洲血统女性的多学科研究
  • 批准号:
    10653186
  • 财政年份:
    2020
  • 资助金额:
    $ 15.13万
  • 项目类别:
Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry
肿瘤免疫环境和乳腺癌差异:针对非洲和欧洲血统女性的多学科研究
  • 批准号:
    10171569
  • 财政年份:
    2020
  • 资助金额:
    $ 15.13万
  • 项目类别:
Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry
肿瘤免疫环境和乳腺癌差异:针对非洲和欧洲血统女性的多学科研究
  • 批准号:
    10404988
  • 财政年份:
    2020
  • 资助金额:
    $ 15.13万
  • 项目类别:
A Cobalt Porphyrin Nanoliposome Adjuvant for MHC-I-Restricted Cancer Peptide Vaccines
用于 MHC-I 限制性癌症肽疫苗的钴卟啉纳米脂质体佐剂
  • 批准号:
    10320831
  • 财政年份:
    2020
  • 资助金额:
    $ 15.13万
  • 项目类别:
A Cobalt Porphyrin Nanoliposome Adjuvant for MHC-I-Restricted Cancer Peptide Vaccines
用于 MHC-I 限制性癌症肽疫苗的钴卟啉纳米脂质体佐剂
  • 批准号:
    10557071
  • 财政年份:
    2020
  • 资助金额:
    $ 15.13万
  • 项目类别:
Multidisciplinary Approaches to Tumor Immunology
肿瘤免疫学的多学科方法
  • 批准号:
    10248383
  • 财政年份:
    2019
  • 资助金额:
    $ 15.13万
  • 项目类别:

相似海外基金

The Computational Tumor Immunology Core (CTIC)
计算肿瘤免疫学核心 (CTIC)
  • 批准号:
    10505677
  • 财政年份:
    2022
  • 资助金额:
    $ 15.13万
  • 项目类别:
Exploring association of ganglioside in cutaneous malignant lymphoma with tumor immunology
探索皮肤恶性淋巴瘤中神经节苷脂与肿瘤免疫学的关系
  • 批准号:
    21K08300
  • 财政年份:
    2021
  • 资助金额:
    $ 15.13万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Role of Metabolite Sensing in T cell Homeostasis and Tumor Immunology
代谢物传感在 T 细胞稳态和肿瘤免疫学中的作用
  • 批准号:
    10223175
  • 财政年份:
    2020
  • 资助金额:
    $ 15.13万
  • 项目类别:
Molecular understanding of tumor immunology of malignant pleural mesothelioma targeting human CD26/DPPIV molecule.
针对人 CD26/DPPIV 分子的恶性胸膜间皮瘤肿瘤免疫学的分子理解。
  • 批准号:
    20K07683
  • 财政年份:
    2020
  • 资助金额:
    $ 15.13万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Role of Metabolite Sensing in T cell Homeostasis and Tumor Immunology
代谢物传感在 T 细胞稳态和肿瘤免疫学中的作用
  • 批准号:
    10445240
  • 财政年份:
    2020
  • 资助金额:
    $ 15.13万
  • 项目类别:
Exploring the cell biology, tumor immunology and clinical significance of IL17RB in breast cancer
探索IL17RB在乳腺癌中的细胞生物学、肿瘤免疫学和临床意义
  • 批准号:
    19K18073
  • 财政年份:
    2019
  • 资助金额:
    $ 15.13万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Multidisciplinary Approaches to Tumor Immunology
肿瘤免疫学的多学科方法
  • 批准号:
    9769624
  • 财政年份:
    2019
  • 资助金额:
    $ 15.13万
  • 项目类别:
Multidisciplinary Approaches to Tumor Immunology
肿瘤免疫学的多学科方法
  • 批准号:
    10248383
  • 财政年份:
    2019
  • 资助金额:
    $ 15.13万
  • 项目类别:
Novel mechanism of tumor immunology in anaplastic thyroid carcinoma
甲状腺未分化癌肿瘤免疫学新机制
  • 批准号:
    19K07432
  • 财政年份:
    2019
  • 资助金额:
    $ 15.13万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
anti tumor immunology against GIST through immunecheckpoint mechnism
通过免疫检查点机制对抗GIST的抗肿瘤免疫学
  • 批准号:
    16K09292
  • 财政年份:
    2016
  • 资助金额:
    $ 15.13万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了